Table 4

Relation between changes in purine enzyme activities from baseline and toxicity-related discontinuation of methotrexate treatment. Values are the mean (95% confidence interval)

Toxicity related discontinuation (n=27)
No discontinuation (n=76)All toxicity (n=27)Hepatotoxicity (n=14)
*No significant between-group differences were found with the exception of the decrease of 5`NT from baseline in the group of patients discontinuing methotrexate because of hepatotoxicity compared with no discontinuation (p=0.007).
5`NT0.4 (−1.2 to 2.1)−1.9 (−7.9 to 4.1)−6.1 (−12.9 to 0.7)*
ADA−21.6 (−28.6 to −14.7)−19.1 (−31.4 to −6.8)−14.9 (−25.5 to −4.3)
PNP−78.9 (−109.0 to −48.7)−38.7 (−86.6 to 9.2)−67.6 (−133.6 to −1.5)
HGPRT−2.0 (−3.1 to −0.9)−0.9 (−3.2 to 1.4)−3.4 (−6.5 to −0.4)